PTC Therapeutics, Inc.
HealthcareNASDAQ:PTCT · NASDAQ Global Select
+$0.43 today
Vol 1.07M · Avg 1.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-332.5%
avg -3353.7%
ROIC
37.4%
avg -22.6%
ROA
23.4%
avg -23.3%
Analysis
ROIC is currently the strongest return metric at 37.4% versus its period average of -22.6%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Matthew Klein | Chief Executive Officer & Director | $2.27M | — | 54 | $398,670.00 | 0.48% |
Eric Pauwels | Chief Business Officer | $1.16M | — | 64 | $0.00 | <0.01% |
Pierre Gravier | Chief Financial Officer | $1.09M | — | 40 | $87,318.00 | 0.11% |
Lee Golden | Executive Vice President & Chief Medical Officer | $1.08M | — | 58 | $79,115.00 | 0.10% |
Neil Almstead | Chief Technical Operations Officer | $1.08M | — | 59 | $60,217.00 | 0.07% |
Mark Elliott Boulding | Executive Vice President & Chief Legal Officer | $761,936.00 | — | 65 | $105,212.00 | 0.13% |
Christine Utter | Senior Vice President, Chief Accounting Officer & Head of People Services | $595,537.00 | — | 47 | $70,199.00 | 0.08% |
Allan Steven Jacobson | Co-Founder & Independent Director | $140,000.00 | — | 80 | $21,451.00 | 0.03% |
Linda Montella Carter | Senior Vice President & Chief Information Officer | — | — | — | — | — |
Ellen Cavaleri | Head of Investor Relations | — | — | — | — | — |
Hege Sollie-Zetlmayer | Chief Human Resources Officer | — | — | — | — | — |
Jane Baj | Vice President of Corporate Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
113
$24.80M
Net Sentiment
$24.80M
Net selling
Most Active
Boulding Mark Elliott
32 transactions
1–10 of 113
Analysis
Insiders reported 0 buys worth $0.00 and 113 sells worth $24.80M over the last 12 months. That adds up to net selling of $24.80M. Boulding Mark Elliott was the most active insider with 32 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | +8.5% | +30.0% (15yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +8.5% over three years. Forward estimates point to Revenue at +30.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.50B
Krystal Biotech, Inc.
NASDAQ:KRYS
$9.37B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.58B
Metsera, Inc.
MTSR
$7.43B
Alkermes plc
NASDAQ:ALKS
$7.38B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.06B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.85B
Arcellx, Inc.
ACLX
$6.73B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
Who manages PTCT?
PTC Therapeutics, Inc. (PTCT) lists 12 active executives. The top listed executive is Lee Golden, Executive Vice President & Chief Medical Officer.
Are PTCT insiders buying or selling?
Recent insider activity shows net buying of $10.90M.
Explore More
Continue the stock analysis
Jump to another research area for this company.